T HE ADRENAL MEDULLA functions as a neuroendocrine system to release catecholamine on cholinergic stimulation from the splanchnic sympathetic neurons. Chromaffin cells of the adrenal medulla are the main source for generating high levels of catecholamine, including adrenalin, noradrenalin, and dopamine, in the bloodstream, mediating the fight-or-flight responses as a defense mechanism against the dangerous environment (1).
The adrenal medulla is surrounded by the adrenal cortex, which is involved in the hypothalamic-pituitary-adrenal axis. Glucocorticoids including cortisol can be released from the adrenal cortex in response to chronic stress, affecting digestion, mood, and the immune system (2) . The adrenal medulla and adrenal cortex are interwoven with capillary vessels and thereby interact with each other through their hormones (3) .
The genomic effect of glucocorticoids has been well identified for gene expression in chromaffin cells. Glucocorticoids modulate the expression of specific genes via activation of glucocorticoid receptors (GRs), which act as transcription factors (2) . In addition, the genomic effects of glucocorticoids have been implicated in the control of mRNA or protein stability as well as chromaffin cell differentiation (2) . Typically the genomic effect of glucocorticoids results in increasing catecholamine release through promoting gene expression (2) . However, the nongenomic effects of glucocorticoids on catecholamine release in chromaffin cells have been poorly understood. In humans, short-term treatment with glucocorticoids inhibits the level of catecholamine released from chromaffin cells in the blood stream (4, 5) . Despite the studies at the organism level, it has been mysterious why glucocorticoids cannot inhibit catecholamine release at the cellular level. Here we show that glucocorticoids inhibit catecholamine release induced by repetitive stimulation but not by a single stimulation.
We previously reported that repetitive stimulation of nicotinic acetylcholine receptor (nAChR) induces activitydependent potentiation (ADP) of catecholamine release in chromaffin cells (6, 7) . Here we investigate the signaling mechanism by which glucocorticoids can inhibit ADP of catecholamine release. Glucocorticoids inhibit ADP without affecting calcium influx. Our data suggest that the rapid inhibitory effect of glucocorticoids on ADP is not dependent on the intracellular GR or membrane GR but mediated by blocking vesicle translocation and F-actin disassembly. We provide evidence that glucocorticoids lead to inhibition of F-actin disassembly by suppressing phosphorylation and translocation of protein kinase C (PKC)-and its downstream target myristoylated alanine-rich C kinase substrate (MARCKS).
(DMPP), dexamethasone (DEX), hydrocortisone, and RU-486 were purchased from Sigma (St. Louis, MO). DEX-BSA conjugate is from Steraloids Inc. (Newport, RI). Anti-PKC-and antisynaptotagmin monoclonal antibody were from Transduction Laboratories (Lexington, KY). Anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-phospho-MARCKS polyclonal antibody was from Cell Signaling (Beverly, MA). The enhanced chemiluminescence (Supex) kit was from Neuronex (Pohang, Korea).
Preparation of bovine chromaffin cells
Chromaffin cells were isolated from the bovine adrenal gland medulla by two-step collagenase digestion as previously described (6) . For amperometric measurement and calcium imaging, cells were grown on poly-d-lysine-coated glass coverslips at the density of 1 ϫ 10 5 cells per 35-mm dish. The cells were maintained in DMEM/F-12 (Invitrogen, Carlsbad, CA) containing 10% fetal bovine serum (Hyclone Laboratories, Logan, UT) and 1% antibiotics (Invitrogen). We finished experiments within 48 h after chromaffin cell preparation.
Amperometric measurement
Recordings of chromaffin cells, grown on poly-d-lysine-coated glass coverslips, were performed at room temperature as described previously (7) . Chromaffin cells were buffered with amine-free solution containing 137.5 mm NaCl, 2.5 mm KCl, 2 mm CaCl 2 , 1 mm MgCl 2 , 10 mm d-glucose, and 10 mm HEPES (pH 7.3) titrated by NaOH. Carbon-fiber electrodes were fabricated from 8-m-diameter carbon fibers (Alfa Aesar, Ward Hill, MA). A carbon-fiber electrode backfilled with 3 m KCl connected to the head stage was attached to a single cell. The amperometric current, generated by oxidation of catecholamines, was measured by using an axopatch 200B amplifier (Axon Instruments Inc., Foster City, CA) and operated in the voltage-clamp mode at a holding potential of ϩ 650 mV. Amperometric signals were low-pass filtered at 100 Hz and sampled at 500 Hz. For data acquisition and analysis, pCLAMP 10 software (Axon Instruments) was used. Peak number and peak height of amperometric current were calculated by using IGOR software (Wave Metrics, Lake Oswego, OR). Solutions were exchanged by a local perfusion system that allows complete exchange of medium bathing the cells within 2 sec.
Intracellular free calcium concentration imaging
We performed calcium imaging of single cells with fura-2/AM, as described in detail elsewhere (6) . We performed single-cell calcium imaging experiments with a monochromator-based spectrofluorometric system (DeltaScan Illumination System; DeltaScan Photon Technology International, Inc., Birmingham, NJ).
Total internal reflection fluorescence (TIRF)
TIRF microscopy was used to obtain evanescent field fluorescent images. Briefly, experiments were performed on an Olympus inverted microscope (model IX81; Olympus, Tokyo, Japan) with the Olympus Apo ϫ100 1.65 numerical aperture oil-immersion objective. Fluorescence was excited at 488 nm obtained from 10 mW multiline argon-ion laser with the TIRF slider and emitted through U-MNIB3 filter (Olympus). Images were taken with an intensified charge-coupled device camera (C9100; Hamamatsu, Hamamatsu City, Japan) and analyzed using MetaMorph7 (Molecular Devices, Sunnyvale, CA). Cells were incubated in 200 nm LysoTracker Green for 10 min to stain vesicles, as described in detail elsewhere (8) . After stimulation with 3 m DMPP, the average intensities of whole-cell evanescent field fluorescence were measured for 2 min at 3-sec intervals. The change of evanescent field fluorescence (EFF) was analyzed by subtracting the basal level of EFF intensity.
Recombinant adenoviruses
Adenovirus containing actin-green fluorescent protein (GFP) was provided by Dr. Ashworth (University of Maine, Orono, ME). Chromaffin cells were transfected with adenovirus (1 multiplicity of infection) for 24 h, as described previously (7) .
Cell fractionation and immunoblotting
We performed cell fractionation and immunoblotting as previously described in detail (7) . Cells stimulated as indicated were washed with chilled PBS. To separate the cell lysates into the cytosolic and membrane fraction, cells were suspended in buffer A [10 mm Tris-HCl (pH 7.4), 1 mm EDTA, 0.5 mm EGTA, 10 mm NaCl, 1 mm phenylmethylsulfonyl fluoride, 1 mm Na 3 VO 4 , 1 mm dithiothreitol, 2 mm ascorbic acid, 10 g/ml pepstatin A, 10 g/ml leupeptin, and 10 g/ml aprotinin]. After removing cell debris and organelle by centrifuge at 3000 ϫ g for 15 min, the supernatant was further centrifuged at 100,000 ϫ g for 1 h, and the supernatant was saved as the cytosolic fraction. The pellet was then resuspended in buffer A and saved as the membrane fraction. Proteins were then separated by electrophoresis containing 0.1% sodium dodecyl sulfate and transferred to a nitrocellulose membrane, which was blocked with 5% nonfat dry milk in a solution of 20 mm Tris-HCl (pH 7.4), 140 mm NaCl, and 0.05% Tween 20.
Real-time imaging for F-actin disassembly
Cells were transfected with adenovirus expressing actin-GFP for monitoring F-actin dynamics. Green fluorescent imaging was investigated using an Olympus Fluoview FV1000 confocal laser system with an UPLSAPO ϫ60 Oil (numerical aperture: 1.35) objective. Real-time images (512 ϫ 512 pixels) were acquired at 5-sec intervals for 3 min with a 2 sec/pixel sampling speed.
Statistical analysis
All quantitative data are presented as means Ϯ sem. Comparison between two groups were analyzed by two-tailed unpaired Student's t test or Mann-Whitney test as indicated for individual experiments using Clampfit 10.2 (Axon Instruments). To compare results between more than three groups, we used a one-way ANOVA with post hoc Tukey's honestly significant difference, and the Student-Newman-Keuls test. Statistical significance was set at P Ͻ 0.05.
Results

Glucocorticoids inhibit ADP of catecholamine release
Amperometry was used for real-time measurement of catecholamine release. We investigated the effect of glucocorticoids on the vesicle fusion frequency as well as the total amount of released catecholamine using amperometric measurement. As we previously reported (6, 7), repetitive activation of nAChR gives rise to ADP of catecholamine release. ADP is the increase in neurotransmitter release induced by successive and repetitive stimulation. When chromaffin cells were stimulated three times with DMPP, a selective agonist of nAChR exerting cell depolarization, which provokes calcium influx, ADP of catecholamine release occurred (Fig. 1) . Because glucocorticoids are released from the adrenal cortex and regulate adrenal medulla chromaffin cells, we examined whether glucocorticoids affect ADP with nongenomic manner in a short period of time. DEX, a synthetic glucocorticoid of steroid hormones, was used to study the nongenomic effect of glucocorticoids on ADP. Short-term DEX treatment (500 nm, 5 min) blocked ADP of catecholamine release without affecting the first stimulation-induced basal secretion (Fig. 1, A and B) , suggesting that glucocorticoids inhibit the potentiation process. Cortisol (3 m, 5 min) also inhibited ADP, showing the inhibitory role of glucocorticoids on ADP of catecholamine in the adrenal medulla chromaffin cells (Fig. 1, C and D) . DEX can repress ADP in a concentration-dependent manner (IC 50 324.2 Ϯ 54.5 nm; Hill coefficient 1.5 Ϯ 0.4) (Fig. 1E) .
We previously showed that ADP of catecholamine release can be attributed to the increase of vesicle translocation and vesicle fusion (7) . The number of amperometric spikes (representing fused vesicles) increases upon repetitive stimulation with DMPP (7). The third DMPP stimulation increases the spike frequency, compared with the first stimulation (Fig.  1F) . Short-term treatment with DEX (500 nm, 5 min) inhibited the increase in amperometric spike number (Fig. 1F) as well as the total amount of catecholamine (Fig. 1B) without affecting the first stimulation-induced exocytosis. These data suggest that glucocorticoids repress the repetitive stimulation-induced potentiation by reducing the number of fused vesicles but cannot inhibit the single stimulation-induced exocytosis.
Rapid glucocorticoid effects can be mediated by specific interaction with the cytosolic GR (9) . To investigate whether rapid DEX-induced inhibition of ADP is GR dependent, RU-486 (glucocorticoid antagonist) was applied for 1 h before DEX treatment. Ten-or 50-m RU-486 treatments failed to reverse the inhibitory effect of glucocorticoids ( Fig. 1G and  supplemental Fig. 1C , published as supplemental data on The Endocrine Society's Journals Online web site at http:// endo.endojournals.org), indicating that the inhibitory effect of glucocorticoids on ADP is GR independent. Furthermore, we examined the involvement of membrane bound GR in the inhibitory effect of glucocorticoid by using membrane-impermeable DEX-BSA (BSA conjugate form of dexamethasone) (see supplemental Fig. 1B) . Impermeable DEX-BSA (500 nm, 5 min) could not inhibit ADP, indicating that the inhibitory effect of glucocorticoid is not mediated by membrane bound GR or interaction with membrane. Altogether we suggest that short-term DEX treatment (5 min) suppresses ADP of catecholamine release by reducing the vesicle fusion frequency, which is independent on interactions with membrane or intracellular GR.
Lack of glucocorticoids effect on calcium influx
Because an intracellular calcium influx is known to regulate vesicle exocytosis, we tested whether short-term DEX treatment inhibits calcium influx. DEX treatment (500 nm, 5 min) did not significantly affect the single DMPP-induced calcium influx (Fig. 2A) . To further examine whether DEX might inhibit calcium influx induced by repetitive stimulation, we performed calcium imaging experiments. As pre- -15) . F, DEX blocks the increase in the spike frequency induced by the repetitive stimulation without affecting the first stimulation-induced spike frequency. The spike frequency represents the number of amperometric spikes per 1 sec. G, Inhibitory effect of DEX on ADP of catecholamine release is not reversed by the intracellular glucocorticoid receptor antagonist, RU-486 (RU). Cells were stimulated as described in A, after preincubation in the absence or presence of 10 M RU for 1 h (n ϭ 5-8; P Ͻ 0.01, one-way ANOVA test). Data presented in B, D, E, and F are means Ϯ SEM. *, P Ͻ 0.05; **, P Ͻ 0.01; ***, P Ͻ 0.005 (Mann-Whitney test).
viously reported, three times repetitive stimulation with DMPP leads to a calcium influx with a constant peak level (6). Short-term DEX treatment could not inhibit the calcium influx induced by repetitive stimulation (Fig. 2C) , indicating that short-term DEX treatment has no effect on the DMPPinduced calcium influx. Taken together, these results suggest that the short-term inhibitory effect of glucocorticoids on ADP is not associated with the decrease in calcium influx (Fig. 2) but the decrease in the vesicle fusion frequency (Fig. 1F) .
DEX treatment attenuates activity-induced vesicle translocation
Increase of the vesicle fusion frequency is ascribed to vesicle translocation (6, 7). Because short-term DEX treatment reduced the vesicle fusion frequency, we further examined whether DEX treatment abolishes vesicle translocation. Vesicles were visualized using evanescent field objective-based TIRF microscopy to monitor the movement of large dense-core vesicles (LDCVs) in live cells. The evanescent wave selectively illuminates fluorescent dye within about 400 nm of the plasma membrane-coverslip interface. Evanescent field imaging provides real-time monitoring of vesicle translocation at or near the plasma membrane (10, 11) . In accordance with previous studies (8, 11) , evanescent field fluorescence imaging showed dynamic movement of lysotracker-stained vesicles (Fig. 3A) . DMPP stimulation caused the elevation of EFF intensity (Fig. 3A) , indicating an increase of vesicle translocation toward the plasma membrane. This enlargement of the vesicle pool size near the plasma membrane correlated with the augmentation of the number of amperometric spikes, showing that activity-induced vesicle translocation to the plasma membrane leads to an increase in the number of fused vesicles (Fig. 1F) .
Short-term treatment with DEX blocked the activity-induced increase in EFF (Fig. 3, B and C) , as correlated with a reduction of the fused vesicle number (Fig. 1F) . Therefore, we suggest that short-term treatment with DEX inhibits ADP of catecholamine release via attenuating activity-induced vesicle translocation. 
Glucocorticoids inhibit F-actin disassembly induced by DMPP stimulation
As we previously proved, F-actin dynamics regulates ADP by controlling vesicle translocation and the vesicle fusion frequency (6, 7) . Inhibition of DMPP-induced F-actin disassembly decreases vesicle translocation and the frequency of fusion between vesicles and the plasma membrane (7) . To verify that short-term DEX treatment inhibits DMPP-induced F-actin disassembly, F-actin dynamics was monitored using a confocal laser microscope. Cells were transfected with adenovirus expressing actin-GFP to analyze F-actin disassembly. As a control, DMPP stimulation causes F-actin disassembly within 30 sec after stimulation (Fig. 4A) . Moreover, the cortical F-actin is selectively destroyed by DMPP stimulation, whereas the cytosolic GFP fluorescence remains unchanged, excluding the possibility of a fluorescence decay effect (Fig. 4B) . Short-term treatment of DEX (500 nm, 5 min) or hydrocortisone (3 m, 5 min) reduced cortical F-actin disassembly induced by DMPP stimulation (Fig. 4, C and  4D) , suggesting that the rapid inhibitory effect of glucocorticoid on ADP of catecholamine release is mediated by inhibition of F-actin disassembly.
Glucocorticoids inhibit MARCKS phosphorylation and translocation into the cytosolic fraction
Next, the mechanisms were sought by which short-term DEX treatment blocks F-actin disassembly, which regulates vesicle translocation. It has been shown that phosphorylation of MARCKS regulates F-actin dynamics (12) and thereby affects ADP (7). Because DEX treatment blocked F-actin disassembly, which plays a crucial role in ADP, we examined whether short-term DEX treatment affects phosphorylation of MARCKS. DEX treatment (500 nm, 5 min) reduced the phospho-MARCKS level induced by DMPP stimulation (Fig.  5A ). In addition, DEX treatment blocked translocation of PKC-, which can phosphorylate MARCKS in the membrane fraction (Fig. 5B) (7) . We also validated that hydrocortisone (3 m, 5 min) inhibited PKC-translocation (Fig. 5D) . To further confirm that DEX treatment inhibits translocation of PKC-and thereby suppresses MARCKS phosphorylation, we investigated whether DEX treatment regulates MARCKS translocation into the cytosolic fraction. In line with downregulation of MARCKS phosphorylation (Fig. 5A) , DEX treatment inhibited MARCKS translocation from the membrane to the cytosolic fraction (Fig. 5C ). We also confirmed that hydrocortisone inhibited MARCKS translocation (Fig. 5E ). Taken together, these results suggest that short-term treatment of glucocorticoids inhibits MARCKS translocation into the cytoplasm by blocking MARCKS phosphorylation, thereby attenuating F-actin disassembly and vesicle translocation.
Discussion
This study shows that short-term glucocorticoid treatment inhibits ADP of catecholamine release without affecting the single stimulation-induced exocytosis (Fig. 1, B and D) and suggest that glucocorticoids have the nongenomic effect on inhibition of ADP in a GR-independent manner ( Fig. 1G and  supplemental Fig. 1 ). In addition, glucocorticoids inhibit ADP by reducing the number of fused vesicles (Fig. 1F ) and vesicle translocation (Fig. 3) . Glucocorticoids suppress Factin disassembly, which mediates vesicle translocation (Fig.  4C) . Furthermore, glucocorticoids reduce F-actin disassembly by inhibiting MARCKS phosphorylation and translocation into the cytoplasm (Fig. 5) . Altogether glucocorticoids block ADP of catecholamine release via decreasing PKC--induced MARCKS phosphorylation, which leads to inhibition of F-actin disassembly and vesicle translocation.
It has been reported that the nongenomic effects of glucocorticoids mediate inhibition of ion channels such as nAChR, potassium channel, or voltage-gated calcium channel (13) (14) (15) (16) . However, in our experiments, short-term treatment with glucocorticoids did not affect the calcium influx evoked by nAChR activation in bovine chromaffin cells (Fig.  2) , as correlated with the previous report (15) . Accordingly, there have been no reports showing that short-term glucocorticoid treatment inhibits catecholamine release in chromaffin cells. Here we first describe that short-term treatment with glucocorticoids inhibits repetitive stimulation-induced potentiation of catecholamine release without affecting the calcium influx.
It is unlikely that the rapid inhibitory effect of glucocorticoids on ADP of catecholamine release is mediated by the genomic effect because glucocorticoids were treated for only 5 min. Glucocorticoids show the genomic effect by binding to the intracellular GR that, in turn, regulates gene expression. This process of the genomic effect typically takes at least 30 -60 min (17) .
Nongenomic effects can be mediated by: 1) specific interaction with the cytosolic GR, 2) specific interactions with membrane bound GR, or 3) nonspecific interactions with intracellular machinery (9, 17, 18) . We show that the cytosolic GR is not involved in the inhibitory nongenomic effect on ADP because GR inhibitors (RU-486) cannot reverse the inhibitory effect of glucocorticoids ( Fig. 1G and supplemental  Fig. 1C) . Also, treatment with impermeable DEX-BSA failed to block ADP (supplemental Fig. 1B) , indicating that the inhibitory effect of glucocorticoid is not associated with membrane bound GR. In addition, treatment with DEX (less than 2 min preincubation) cannot reduce ADP (data not shown), whereas treatment with DEX (500 nm, 5 min preincubation) inhibits ADP. Altogether we suggest that the inhibitory effect of glucocorticoids might be mediated by nonspecific interactions with intracellular proteins, not by GR signaling. Several reports show that the nongenomic effect of glucocorticoids is GR independent in neurons (19 -21) . However, the molecular mechanisms by which the non-FIG. 5. Glucocorticoids regulate MARCKS phosphorylation and translocation into the cytosol. A, DEX blocks MARCKS phosphorylation induced by DMPP stimulation. Then 3 M DMPP were applied in the absence or presence of 500 nM DEX for 5 min. Cell lysates were subjected to SDS-PAGE after stimulation and immunoblotted with anti-phospho-MARCKS antibody. Immunoblotting with the GAPDH antibody was performed for normalization. Immunoblotting was quantified by densitometry and normalized as an arbitrary unit (A.U.). B, DEX inhibits translocation of PKC-into the membrane fraction (Memb. frac.). Samples from the membrane fraction were immunoblotted with anti-PKC-antibody. C, Short-term treatment with DEX reduces translocation of MARCKS into the cytosolic fraction (Cyto. frac.). D, Hydrocortisone (3 M, 5 min) also inhibits translocation of PKC-into the membrane fraction. Samples from the membrane fraction were immunoblotted with anti-PKC-antibody. E, Short-term treatment with hydrocortisone reduces translocation of MARCKS into the cytosolic fraction. Immunoblotting with the GAPDH and synaptotagmin antibodies was performed for normalization of the cytosolic and membrane fraction, respectively. Data are means Ϯ SEM values. *, P Ͻ 0.05 (Student's t test).
genomic effect of glucocorticoids can inhibit ADP of catecholamine release still remain to be elucidated.
The adrenal medulla and adrenal cortex are interwoven with capillary vessels to interplay each other through their hormones (3) . Importantly, glucocorticoid level in the venous effluent or capillary vessels from the adrenal gland is 100-fold higher than in the peripheral circulation of blood in response to stress (22, 23) , indicating that glucocorticoid concentration in the adrenal medulla is much higher than in the blood. By this reason, we believe that the concentration of glucocorticoids applied in this report could be the physiological level in the adrenal medulla chromaffin cells.
It has been reported that an iv acute injection of glucocorticoids in healthy humans represses the level of catecholamine, thereby inhibiting the sympathetic nervous system (4, 5) . However, the signaling pathway by which inhibitory effect of glucocorticoids can be mediated has not proved at the cellular level. We suggest that glucocorticoids, released from the adrenal cortex in response to chronic stress, might inhibit the fight-or-flight response by repressing ADP of catecholamine release in the adrenal medulla chromaffin cells.
